Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride

Indian Journal of Pharmaceutical Sciences

Volumn 74, Issue 5, 2012, Pages 434-442

  Shah, M ^a   Agrawal, Y K ^a   Garala, K ^b   Ramkishan, A ^c  

^a GUJARAT FORENSIC SCIENCES UNIVERSITY   (India)

^b Atmiya Institute of Pharmacy   (India)

^c GOVERNMENT OF INDIA   (India)

Author keywords

Central composite design; ciprofloxacin HCl; encapsulation; particle size; solid lipid nanoparticle

Indexed keywords

CIPROFLOXACIN; NANOCARRIER; SOLID LIPID NANOPARTICLE;

ARTICLE; DRUG EFFICACY; DRUG SCREENING; ELECTROPHORETIC MOBILITY; EXPERIMENTAL DESIGN; NANOENCAPSULATION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SLOW DRUG RELEASE; SURFACE CHARGE; ZETA POTENTIAL;

EID: 84875951568     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.108419     Document Type: Article

References (44)

1. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: In vitro and in vivo studies. Drug Dev Ind Pharm 2003;29:215-21.
2. Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv 2011;2011:863734.
3. Egger SF, Ruckhofer J, Alzner E, Hell M, Hitzl W, Huber-Spitzy V, et al. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res 2001;33:117-20.
4. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 2004;275:171-87.
5. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
6. Schwarz C, Mehnert W, Lucks J, Müller R. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96.
7. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96.
8. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31-48.
9. Shegokar R, Singh KK, Müller RH. Production and stability of stavudine solid lipid nanoparticles-From lab to industrial scale. Int J Pharm 2011;416:461-70.
10. Gokce EH, Ozyazici M, Souto EB. Nanoparticulate strategies for effective delivery of poorly soluble therapeutics. Ther Deliv 2010;1:149-67.
11. Torchilin VP. editor. Nanoparticulates as Drug Carriers. London: Imperial College Press; 2006.
12. Gasco MR, Morel S, Ugazio E, Cavalli R. Thymopentin in solid lipid nanoparticles. Int J Pharm 1996;132:259-61.
13. Reithmeier H, Herrmann J, Gpferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release 2001;73:339-50.
14. Olbrich C, Gessner A, Schröder W, Kayser O, Müller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene- cytotoxicity testing and mouse serum adsorption. J Control Release 2004;96:425-35.
15. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:491-504.
16. Yuan H, Jiang SP, Du YZ, Miao J, Zhang XG, Hu FQ. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids Surf B Biointerfaces 2009;70:248-53.
17. Yassin AE, Anwer MK, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA. Optimization of 5-fluorouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer. Int J Med Sci 2010;7:398-408.
18. Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem Pharm Bull 2010;58:650-5.
19. Trotta M, Gallarate M, Battaglia L, Chirio D. Cisplatin loaded SLN produced by coacervation technique. J Drug Deliv Sci Technol 2010;20:343-7.
20. Trotta M, Gallarate M, Battaglia L, Peira E. Peptide loaded solid lipid nanoparticles prepared through coacervation technique. Int J Chem Eng 2011;2011:1-6.
21. François G, Katz JL. Nanoparticles and nanocapsules created using the Ouzo effect: Spontaneous emulsification as an alternative to ultrasonic and high-shear devices. ChemPhysChem 2005;6:209-16.
22. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145-9.
23. Themistocles P, Gary D, Michael A, Panayotis E. Quantitative calculations in Pharmaceutical Practice and Research. New York: VCH Publishers; 1993. p. 189-209.
24. Gohel MC, Panchal MK, Jogani VV. Novel mathematical method for quantitative expression of deviation from the Higuchi model. AAPS PharmSciTech 2000;1:E31.
25. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
26. Banker GS, Rhodes CT. Modern pharmaceutics. Basel: Macel Dekker Inc; 2002.
27. Reza M, Quadir MA, Haider SS. Development of theophylline sustained release dosage form based on kollidon SR. Pak J Pharm Sci 2002;15:63-70.
28. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003;257:153-60.
29. Allan FM, Barton PD. CRC Handbook of Solubility Parameters and Other Cohesion Parameters. Boca Raton, Florida: CRC; 1983.
30. Barton AF. Applications of solubility parameters and other cohesion parameters in polymer science and technology. Pure Appl Chem 1985;57:905-12.
31. Savova M, Kolusheva T, Stourza A, Seikova I. The use of group contribution method for predicting the solubility of seed polyphenols of Vitis vinifera L. within a wide polarity range in solvent mixtures. J Univ Chem Technol Metallurgy 2007;42:295-300.
32. Srinivas K, King JW, Monrad JK, Howard LR, Hansen CM. Optimization of subcritical fluid extraction of bioactive compounds using Hansen solubility parameters. J Food Sci 2009;74:E342-54.
33. Li Y, Taulier N, Rauth AM, Wu XY. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res 2006;23:1877-87.
34. Long C, Zhang L, Qian Y. Preparation and crystal modification of ibuprofen loaded solid lipid microparticles. Chin J Chem Eng 2006;14:518-25.
35. Hansen CM. Hansen Solubility Parameters: A User's Handbook. Florida: CRC; 2007.
36. Vaughan CD. Using solubility parameters in cosmetics formulation. J Soc Cosmet Chem 1985;36:319-33.
37. Ledolter J. Designed experiments in nanotechnology: Reviewing the statistical analyses of five studies. Qual Technol Quant Manag 2011;8:183-209.
38. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release 2006;110:422-30.
39. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: A factorial design study. Int J Pharm 2002;238:77-92.
40. Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: Estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull 1995;43:1412-5.
41. Shi L, Li Z, Yu L, Jia H, Zheng L. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Dispers Sci Technol 2011;32:1-9.
42. Yang YY, Chung TS, Bai XL, Chan WK. Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method. Chem Eng Sci 2000;55:2223-36.
43. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine 2011;6:683-92.
44. Rahman Z, Zidan AS, Khan MA. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm 2010;76:127-37.